What should be the optimal cut-off of serum 1,3-β-d-glucan for the detection of invasive pulmonary aspergillosis in patients with haematological malignancies?

References

• Del Bono V, Mikulska M, Viscoli C. Invasive aspergillosis: diagnosis, prophylaxis and treatment. Curr Opin Hematol 2008;16:586–93.
   Google Scholar
• Ke dzierska A, Kochan P, Pietrzyk A, Kędzierska J. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1,3)-beta-d-glucan antigens. Eur J Clin Microbiol Infect Dis 2007;26:755–66.
   PubMedGoogle Scholar
• Marty FM, Koo S. Role of (1,3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009;47(Suppl 1):S233–40.
   Google Scholar
• Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Beta-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 2011;52:750–70.
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, . Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004;39:199–205.
   PubMed Web of Science ®Google Scholar
• Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, . 1,3-Beta-d-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008;46: 878–85.
   PubMed Web of Science ®Google Scholar
• Pazos C, Pontón J, Del Palacio A. Contribution of (1,3)-beta-d-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005;43: 299–305.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, . Multicenter clinical evaluation of the (1,3)-beta-d-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005;41: 654–9.
   PubMed Web of Science ®Google Scholar
• Alexander BD, Smith PB, Davis RD, Perfect JR, Reller LB. The (1,3)-beta-d-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010;48:4083–8.
   PubMedGoogle Scholar
• Racil Z, Kocmanova I, Lengerova M, Weinbergerova B, Buresova L, Toskova M, . Difficulties in using 1,3-{beta}-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies—high frequency of false-positive results and their analysis. J Med Microbiol 2010;59:1016–22.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–21.
   PubMed Web of Science ®Google Scholar
• Hachem RY, Kontoyiannis DP, Chemaly RF, Jiang Y, Reitzel R, Raad I. Utility of galactomannan enzyme immunoassay and (1,3)-beta-d-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009;47: 129–33.
   PubMed Web of Science ®Google Scholar
• Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of (1,3)-beta-d-glucan assay for invasive fungal disease. Clin Infect Dis 2009;49:1650–9.
   PubMed Web of Science ®Google Scholar
• Kato K, Onoda S, Asano J, Fukaya S, Yoshida S. Evaluation of the clinical cutoff level of serum (1,3)-beta-d-glucan in patients with connective tissue diseases complicated by deep fungal infections. Mod Rheumatol 2010;20: 366–9.
   PubMedGoogle Scholar
• Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, McGinnis MR, Ostrosky-Zeichner L. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006;44:267–72.
   PubMed Web of Science ®Google Scholar
• Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1,3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008;46:1009–13.
   PubMed Web of Science ®Google Scholar
• Marty FM, Lowry CM, Lempitski SJ, Kubiak DW, Finkelman MA, Baden LR. Reactivity of (1,3)-beta-d-glucan assay with commonly used intravenous antimicrobials. Antimicrob Agents Chemother 2006;50:3450–3.
   PubMed Web of Science ®Google Scholar
• Metan G, Agkus C, Buldu H, Koc AN. The interaction between piperacillin/tazobactam and assays for Aspergillus galactomannan and 1,3-beta-d-glucan in patients without risk factors for invasive fungal infections. Infection 2010;38:217–21.
   PubMed Web of Science ®Google Scholar
• Iossifova Y, Reponen T, Sucharew H, Succop P, Vesper S. Use of (1–3)-beta-d-glucan concentrations in dust as a surrogate method for estimating specific fungal exposures. Indoor Air 2008;18:225–32.
   PubMed Web of Science ®Google Scholar
• Nagano Y, Walker J, Loughrey A, Millar C, Goldsmith C, Rooney P, . Identification of airborne bacterial and fungal species in the clinical microbiology laboratory of a university teaching hospital employing ribosomal DNA (rDNA) PCR and gene sequencing techniques. Int J Environ Health Res 2009;19:187–99.
   PubMed Web of Science ®Google Scholar
• Kelaher A. Two non-invasive diagnostic tools for invasive aspergillosis: (1–3)-beta-d-glucan and the galactomannan assay. Clin Lab Sci 2006;19:222–4.
   PubMedGoogle Scholar